Antibody-Drug Conjugate (ADC) Target Proteins
Non-secretory:The target antigen should be non-secretory to avoid excessive secretion of antigens causing non-specific binding of antigen-antibody complexes in circulation, which would lead to non-specific binding of ADCs outside the tumor site, thereby reducing drug targeting and potentially increasing safety risks[2].
Internalization Properties:After binding with antibody, the target antigen should be able to effectively internalize into tumor cells, ensuring that ADC complexes enter cells through endocytosis, and then promote rapid release of cytotoxic payloads through appropriate intracellular transport pathways[3] to exert anti-tumor effects.
Product List
Product Features
Comprehensive coverage of 90+ hot ADC target proteins;
Multiple species and tags;
Proteins with uniform structure and high purity verified by SEC-MALS;
High bioactivity validated by ELISA/SPR/BLI/FACS, etc.
Validation Data
High purity verified by SEC-MALS
The purity of Mouse PSMA Protein, Fc Tag (Cat. No. PSA-M5266) is more than 90% and the molecular weight of this protein is around 240-280 kDa verified by SEC-MALS.
The purity of Biotinylated Human LRRC15, His,Avitag (Cat. No. LR5-H82E4) is more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
The binding activity verified by ELISA
Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Human PSMA, His Tag (Cat. No. PSA-H52H3) with a linear range of 2-39 ng/mL (QC tested).
Protocol
Immobilized Human TROP-2, His Tag (Cat. No. TR2-H5223) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
Protocol
Immobilized Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H52P7) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.2-3 ng/mL (QC tested).
Protocol
Immobilized Human B7-H4, His Tag (Cat. No. B74-H5222) at 2 μg/mL (100 μL/well) can bind Anti-B7-H4 MAb (Human IgG1) with a linear range of 0.2-6 ng/mL (QC tested).
ProtocolThe binding activity verified by SPR
Captured Trop2 antibody on CM5 chip via anti-mouse antibodies surface can bind Human TROP-2, His Tag (Cat. No. TR2-H5223) with an affinity constant of 5.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Anti-Cadherin-17 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human Cadherin-17, His Tag (Cat. No. CA7-H52H3) with an affinity constant of 2.9 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Mouse Anti-Nectin-4 Antibody (Mouse IgG1) captured on CM5 chip via anti-mouse antibodies surface can bind Human Nectin-4, His Tag (Cat. No. NE4-H52H3) with an affinity constant of 58.2 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Biotinylated Human FOLR1, His,Avitag (Cat. No. FO1-H82E2) immobilized on SA Chip can bind Folic acid-BSA with an affinity constant of 83.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
ProtocolThe binding activity verified by BLI
Loaded Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 on Protein A Biosensor, can bind Human B7-H3 Protein, His Tag (Cat. No. B73-H52E2) with an affinity constant of 479 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, His,Avitag (Cat. No. RO1-H82E6) on SA Biosensor, can bind Zilovertamab with an affinity constant of 0.252 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
ProtocolResources
Webinar playback and appointment
Resource download
![[Flyer]Fucntional Cell Lines and Development Service](https://console.acrobiosystems.com/public/images/ADC_Antibody/1223_04.png)
References
- [1] Damelin Marc, Zhong Wenyan, Myers Jeremy, et al. Evolving Strategies for Target Selection for Antibody-Drug Conjugates.[J]. Pharmaceutical research, 2015, 32(11):3494-507. DOI: 10.1007/s11095-015-1624-3.
- [2] Ritchie Michael, Tchistiakova Lioudmila, Scott Nathan, et al. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates.[J]. mAbs, 2013, 5(1):13-21. DOI: 10.4161/mabs.22854.
- [3] Donaghy Heather, . Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.[J]. mAbs, 2016, 8(4):659-71. DOI: 10.1080/19420862.2016.1156829.
- ADC Target Proteins
- Product List
- Product Features
- Validation Data
- Resources
- References